IPO Journey
FibroBiologics, Inc.
IPO Date: April 1, 2026 · 3 filings tracked
Final Offer Terms
Ticker
FBLG
Exchange
Nasdaq Capital Market
Offer Price
$1.32
Shares Offered
1,028,788
Estimated Proceeds
$1.4M
Expected Listing
April 02, 2026
Underwriters
Led by H.C. Wainwright & Co., LLC
Filing Timeline
1
S-1
December 23, 2025
- Pioneering cell-based therapy platform using human dermal fibroblasts
- Targeting high-need chronic conditions including multiple sclerosis and psoriasis
2
S-1
March 27, 2026
- Proprietary platform utilizing human dermal fibroblasts for regenerative medicine
- Extensive intellectual property portfolio featuring over 150 global patents
Changes from previous filing
- ▸ Final offer price: $4.4 per share
- ▸ Shares offered: 1,136,363
- ▸ Estimated proceeds: $4M
- ▸ Underwriters: H.C. Wainwright & Co., LLC
424B4
Final Pricing
April 1, 2026
- Pioneering fibroblast cell reprogramming for chronic disease treatment
- Targeting high-demand medical fields including wound healing and MS
Changes from previous filing
- ▸ Final offer price: $1.32 per share
- ▸ Shares offered: 1,028,788
- ▸ Estimated proceeds: $1M
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.